Apidra SoloStar 100 units/ml solution for injection in a pre-filled pen
*Company:
SANOFIStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company

Updated on 01 April 2025
File name
1.3.1 SPC APIDRA Ireland PRAC cutaneous amyloidosis (7).pdf
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 06 March 2025
File name
1.3.1 SPC APIDRA Ireland PRAC cutaneous amyloidosis.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 17 December 2021
File name
1.3.2 Mock-up PIL SoloStar IE.pdf
Reasons for updating
- Change to section 6 - what the product contains
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - marketing authorisation holder
- Change to section 6 - marketing authorisation number
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 15 February 2021
File name
1.3.2 Mock-up PIL SoloStar IE Approved on 05 November 2020.pdf
Reasons for updating
- Improved presentation of PIL
Updated on 19 October 2020
File name
1.3.2 Mock-up PIL SoloStar IE 786319 PRAC cutaneous amyloidosis.pdf
Reasons for updating
- Improved presentation of PIL
Updated on 07 September 2020
File name
1.3.2 IE Mock-up PIL SoloStar 770114 Malta rep update SA1770.pdf
Reasons for updating
- Improved presentation of PIL
Updated on 03 September 2020
File name
1.3.1 SPC APIDRA Ireland PRAC cutaneous amyloidosis (1).pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.2 - Pharmacokinetic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 02 April 2020
File name
1.3.2 IE Mock-up PIL SoloStar 770114 Malta rep update SA1770.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 11 September 2019
File name
Apidra1.3.2 Mock-up PIL SoloStar 544168 Ireland CP split SA1019-21.pdf
Reasons for updating
- Joint PIL superseded by individual PILs
Free text change information supplied by the pharmaceutical company
Replace UK/Ireland PIL with Ireland only PIL
Updated on 01 April 2019
File name
PIL Mock up Apidra SoloStar 544458 Remove OptiPen SA914-16.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
Updated on 29 March 2019
File name
SPC APIDRA Ireland Remove OptiPen SA914-16.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 24 October 2018
File name
NEW PIL Apidra SoloStar.pdf
Reasons for updating
- XPIL Updated
Updated on 16 October 2018
File name
NEW PIL Apidra SoloStar.pdf
Reasons for updating
- Improved presentation of PIL
Updated on 29 May 2018
File name
Apidra SoloStar injection in a pre-filled pen PIL.pdf
Reasons for updating
- New PIL for new product
Updated on 29 May 2018
File name
SPC Apidra vial cartridge and pre-filled pen IE.docx
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
SANOFI
Address:
Citywest Business Campus, Dublin 24, IrelandMedical Information E-mail:
iemedinfo@sanofi.comTelephone:
+353 1 4035600